News > AstraZeneca's cancer drug fails to meet main goal in Covid-19 trials
AstraZeneca's cancer drug fails to meet main goal in Covid-19 trials
![](https://www.deccanherald.com/sites/dh/files/articleimages/2020/11/12/2020-10-26t105400z1967069643rc2aqj9mw9ukrtrmadp3health-coronavirus-snapshotjpg-914649-1605169048.jpg)
Deccan Herald | 12/11/2020 03:50 PM | Click to read full article
AstraZeneca Plc said on Thursday its blood cancer treatment, Calquence, failed to meet the main goal of mid-stage trials, testing it in patients hospitalised with respiratory symptoms of Covid-19.
The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its Covid-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination.